Piper Jaffray Companies set a $23.00 price objective on Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a research note published on Friday morning. The brokerage currently has a hold rating on the stock.

A number of other analysts also recently commented on the stock. BTIG Research upgraded shares of Teva Pharmaceutical Industries Limited from a neutral rating to a buy rating and set a $24.00 target price on the stock in a report on Monday, September 11th. TheStreet downgraded shares of Teva Pharmaceutical Industries Limited from a c- rating to a d+ rating in a report on Friday, August 25th. Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a hold rating to a buy rating and set a $34.17 price target on the stock in a report on Monday, July 24th. Credit Suisse Group lowered shares of Teva Pharmaceutical Industries Limited from a neutral rating to an underperform rating and cut their price target for the company from $25.00 to $13.00 in a report on Wednesday, August 23rd. Finally, Goldman Sachs Group, Inc. (The) restated a neutral rating and set a $21.00 price target (down previously from $28.00) on shares of Teva Pharmaceutical Industries Limited in a report on Thursday, August 31st. Five analysts have rated the stock with a sell rating, eighteen have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited has an average rating of Hold and a consensus price target of $28.72.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded up 1.66% on Friday, hitting $15.94. 19,658,567 shares of the stock were exchanged. Teva Pharmaceutical Industries Limited has a one year low of $15.22 and a one year high of $45.85. The firm’s 50-day moving average is $16.91 and its 200-day moving average is $26.76. The company’s market cap is $16.20 billion. Teva Pharmaceutical Industries Limited also was the target of unusually large options trading activity on Wednesday. Stock traders bought 29,656 put options on the company. This represents an increase of 231% compared to the typical daily volume of 8,957 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same quarter in the previous year, the firm earned $1.25 earnings per share. The firm’s revenue for the quarter was up 12.9% compared to the same quarter last year. On average, equities analysts forecast that Teva Pharmaceutical Industries Limited will post $4.28 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Teva Pharmaceutical Industries Limited (TEVA) Given a $23.00 Price Target at Piper Jaffray Companies” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/teva-pharmaceutical-industries-limited-teva-given-a-23-00-price-target-at-piper-jaffray-companies/1615975.html.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 14th. Investors of record on Tuesday, August 29th were issued a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a dividend yield of 2.13%. The ex-dividend date was Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is currently -15.36%.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. San Francisco Sentry Investment Group CA bought a new stake in shares of Teva Pharmaceutical Industries Limited during the 2nd quarter worth $106,000. Kistler Tiffany Companies LLC boosted its holdings in shares of Teva Pharmaceutical Industries Limited by 74.7% during the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after buying an additional 1,571 shares during the period. Bronfman E.L. Rothschild L.P. boosted its holdings in shares of Teva Pharmaceutical Industries Limited by 2.6% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after buying an additional 94 shares during the period. FNY Managed Accounts LLC bought a new stake in shares of Teva Pharmaceutical Industries Limited during the 1st quarter worth $123,000. Finally, Sterling Investment Advisors Ltd. boosted its holdings in shares of Teva Pharmaceutical Industries Limited by 2.6% during the 1st quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after buying an additional 100 shares during the period. 56.77% of the stock is owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.